Genentech (NYSE: DNA), the manufacture of Avastin, a treatment for patients with advanced lung, colon, or breast cancer, is scheduled to report Q2 EPS on July 14. DNA August option implied volatility of 29 is near its 26-week average according to Track Data, suggesting non-directional price movement.
Financial Select Sector-XLF overall volatility at 42; 26-week average is 34
Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

